Navigation Links
WavePharma Unveils Proprietary Chitosan-Based Delivery System for Controlled Release of Key Ingredients in Personal Care Products
Date:12/11/2013

New Orleans, LA (PRWEB) December 11, 2013

WavePharma, LLC, developer of an innovative, extended release and transdermal delivery technology, WP-ChitosanTM, announced today the launch of its modified chitosan for use in the multi-billion dollar cosmetics and pharmaceutical industries. WavePharma is actively seeking development partners to integrate these materials into their personal and skin care formulations.

Native, unmodified chitosan comes from chitin, a natural substance that has been a mainstay in many skin and hair care products for years because of its moisturizing, protective, elastic, antibacterial/antifungal, and biodegradable properties. WavePharma’s modified chitosan retains these properties, plus unlocks premium benefits such as adjustable water retention (hydration), custom bonding of molecules or active ingredients, superior adhesion compared with market leading products, the ability to control the thickness of gels and creams, as well as the ability to control the release of active ingredients and therapeutic agents.

“Our WP-chitosan is more than just a technical advancement, a new feature, or even a new product; it’s a new material. It is chitosan-based, but it’s chemically and physically different than non-modified chitosan and has a number of novel, useful properties to advance skin care, transdermal delivery of active agents, and hair care,” said Jack Foster, CEO of WavePharma.

Much of the WP-chitosan proof-of-concept work to date was sponsored by a market leader in eye medications and focused on controlled release of drugs in the eye. WP-chitosan modified pharmaceutical agents demonstrated long-term retention on the cornea and extended agent delivery profiles and bioavailability. WavePharma is evaluating chitosan-enhanced products for improved retention of actives for the skin and hair. The company has engaged innovation solutions leader Emergent Technologies, Inc. to identify new applications and secure ‘cosmeceutical’ partners looking for science-based solutions for differentiated products using this novel and proprietary delivery system.

“The potential applications of WP-chitosan technology range from extending the efficacy of sunscreen on the skin to creating the ultimate moisturizer that attracts and retains water,” said Kris Looney, Emergent Technologies President. “We anticipate the benefits of this technology will enhance products by improving their performance, satisfying consumer desires for greener products while producing differentiation for our select industry partners increasing their profit margins.”

For additional information about the technology and partnership opportunities, interested parties should visit http://www.wp-chitosan.com.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11410209.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MedTRACK Unveils Partnering Tool for J.P. Morgan Healthcare Conference
2. Wake Forest Baptist Medical Center Unveils Historic World-Class Biotech Research & Innovation Center in Downtown Winston-Salems Growing Piedmont Triad Research Park
3. SPYru™ unveils "The Uberwater"
4. Synteract Unveils New Branding at DIA 2012 to Support Enhanced Commercial Strategy
5. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
6. Opedix® Kinetic Health Gear Unveils New KNEE-Tec™ Knee Support Tights Shown to Reduce Quadriceps Muscle Fatigue and Knee Pain
7. Opedix® Joint Support Compression Apparel Unveils New CORE-Tec™ Shorts, Tested to Improve Core Stability, and Offer Support for Low Back Pain during Athletic Activities
8. Microsoft Unveils Dynamics GP 2013 – A Landmark Release to the ERP Solution
9. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013
10. Genesis Biosystems Unveils Innovative Skin Treatment at Esthétique SPA International Trade Show
11. Family Tree DNA Unveils $39 DNA Test in Major Step Toward Universal Access by Individuals to their Own Genetic Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):